Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
FDA approval announcement for ofatumumab
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
A full genome search in multiple sclerosis.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
A genetic screen identifies genes essential for development of myelinated axons in zebrafish.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Safety Study of Interferon Beta-1a for Acute Stroke
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Novel MS Drug Offers Good Functional Outcomes
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
Alemtuzumab for the Treatment of Multiple Sclerosis
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.

Pages